Actively Recruiting
TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients
Led by University Hospital, Basel, Switzerland · Updated on 2025-11-19
30
Participants Needed
1
Research Sites
253 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Aim of the study is to investigate the efficacy and safety of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with advanced pre-treated non-small cell lung cancer (NSCLC).
CONDITIONS
Official Title
TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand the study and provide signed informed consent
- Age 18 years or older
- Performance status of 0 or 1 on the ECOG scale
- Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
- Disease progression after at least one standard therapy with no approved curative options
- Presence of at least one accessible tumor lesion or metastasis for tissue collection
- Willingness to undergo surgical intervention (resection or biopsy) to collect tumor tissue
- Adequate pulmonary, cardiovascular, hematological, hepatic, and renal function as judged by the investigator
- Negative pregnancy test in women of childbearing potential, peri-menopausal women, or women with less than 2 years of menopause
You will not qualify if you...
- Active central nervous system (CNS) metastases, unless stable for at least 1 month after treatment
- Presence of an active second malignancy
- Significant uncontrolled diseases including autoimmune, immunodeficient, pulmonary, cardiac, or vascular conditions
- Prior immune-related adverse events preventing re-challenge with immune checkpoint inhibitors or immunomodulatory agents
- Use of immunosuppressive treatments that would interfere with study therapies
- Severe active or uncontrolled infections requiring treatment
- Any other condition or allergy contraindicating study interventions
- Contraindications for planned treatments or procedures
- Pregnancy, breastfeeding, or unwillingness to use effective contraception until study end
- Known hypersensitivity to study therapies or drugs used for TIL production
- Known HIV infection or positive HIV test at screening
- Known hepatitis B or hepatitis C infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Medical Oncology, University Hospital Basel
Basel, Canton of Basel-City, Switzerland, 4031
Actively Recruiting
Research Team
D
David König, Dr. med.
CONTACT
H
Heinz Läubli, Prof. Dr. med.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here